Ivantis and Glaukos Clash in 1st Head-to-Head MIGS Trial

A study accepted for publication in the journal Ophthalmology could give Ivantis a competitive advantage against one of the top players in the micro invasive glaucoma surgery space.  Dubbed, “COMPARE,” the study pitted Ivantis’ Hydrus Microstent against two Glaukos iStent Trabecular Micro-bypass stents, for the treatment of open-angle glaucoma in a standalone procedure. Irvine, CA-based Ivantis said the study included 152 patients with mild to late-moderate stage disease and no previous glaucoma surgery. The study was conducted at 12 centers in nine countries outside of the US. It was designed to compare the safety and effectiveness of both devices for lowering IOP and reducing eye-drop medication. Some of the findings show that 47% of eyes in the Hydrus Microstent group were medication free, compared to 24% of eyes in the two iStent group. The findings also show medication use was reduced on average by 1.6 medications, or 61%, in the Hydrus Microstent group, compared to a reduction of one medication, or 37%, in the two iStent group. In addition, 73% of patients receiving the Hydrus Microstent achieved at least a 20% reduction in IOP while on fewer medications, compared to 47% of the two iStent eyes. Randy Craven, MD, Chief, Wilmer Eye Institute at Johns Hopkins University in Bethesda, MD, and an investigator in the trial said the COMPARE Trial is a necessary and highly anticipated study. "It is the...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news